



Role of Non-coding RNAs in Cancer: Markers in Disease Progression and Therapeutics

Guest Editor:

Dr. Balaji Krishnamachary

Postdoctoral Research Fellow,
University of Kansas Medical
Center, Kansas City, KS 66160,
USA

Deadline for manuscript
submissions:

closed (15 March 2022)

Message from the Guest Editor

Dear Colleagues,

Long non-coding RNAs (lncRNAs) are a novel class of non-coding RNAs which are longer than 200 bp and do not have protein-coding ability. The literature suggests that lncRNAs are important regulators of various fundamental cellular processes and have been highlighted as important potential therapeutic targets. The Special Issue would like to focus on the following topics:

1. Role of circulating non-coding RNAs in cancer diagnosis and progression;
2. Potential role of lncRNA–miRNA–mRNA and their interactions in cancer diagnosis and therapeutics;
3. Creating a database of regulatory lncRNAs and its miRNA targets in cancer progression and therapeutics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI